CTLA4 and head and neck squamous cell carcinoma: In this study, we identified key factors influencing the response to neoadjuvant immunotherapy with durvalumab (anti-PD-L1) monotherapy and its combination with tremelimumab (anti-CTLA-4) in HNSCC.